Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial

Fig. 3

Plasma total homocysteine (tHcy) after 1 month of treatment at 100 mg/kg/day (light grey) or 250 mg/kg/day (dark grey) of betaine in pyridoxine non responsive CBS (pnrCBS) (A) and cblC patients (B). No significant differences were observed with betaine dose (− 9.79 [− 23.99; 4.41], p 0.14) or pathology (19.97 [− 15.76; 55.71], p 0.23) on plasma tHcy concentrations after one month of treatment

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172